DailySpaceLAC Med Berhad
5341 · Main Market主板 · annual reports 2025 to 2025, 592 entries read2025 至 2025 年报，共读出 592 条
The company这家公司
LAC Med Berhad is a supplier and integrator of medical devices and related services. LAC Medical was incorporated in 2003 and began business operations in 2004. Its distribution business involves partnerships with 11 global brands, including Philips, Samsung, Stryker and Abbott.LAC Med Berhad 是一家医疗器械及相关服务的供应商与集成商。LAC Medical 于 2003 年注册成立，并于 2004 年开始营业。其分销业务涉及与 11 个全球品牌的合作，包括 Philips、Samsung、Stryker 及 Abbott。
Source: annual report 2025, pages 7, 28, 29.出处：2025 年年报第 7、28、29 页。
In 2025, total revenue was RM201.7 million, with the medical device distribution segment generating RM177.2 million or 88% of total revenue. By activity, supply and integration of medical equipment was RM128,569,063, supply of medical equipment was RM48,563,944, and supply of related products and services totaled RM16,716,923 and RM7,805,152 across two revenue streams. Geographically, Malaysia contributed RM199,917,280 and Indonesia contributed RM1,737,802.2025 年，总营业额为 RM201.7 million，其中医疗器械分销部门贡献 RM177.2 million，占总营业额的 88%。按业务划分，医疗设备的供应与集成占 RM128,569,063，医疗设备供应占 RM48,563,944，相关产品与服务的供应在两项业务中分别占 RM16,716,923 与 RM7,805,152。按地域划分，马来西亚贡献 RM199,917,280，印度尼西亚贡献 RM1,737,802。
Source: annual report 2025, pages 35, 168, 185.出处：2025 年年报第 35、168、185 页。
The four largest holders are: Liew Yoon Poh holds 83,678,700 shares (20.92%), Chan Yue Mun holds 74,416,100 shares (18.61%), Giam Teck Eng holds 65,416,100 shares (16.35%), and Liew Yoon Kit holds 65,416,100 shares (16.35%). Pledged securities accounts include Alliancegroup Nominees (Tempatan) Sdn Bhd Pledged Securities Account for Taiyang Assets Sdn Bhd with 2,505,700 shares (0.63%), RHB Nominees (Tempatan) Sdn Bhd Pledged Securities Account For Hilary Fernandez with 1,332,500 shares (0.33%), and Maybank Nominees (Tempatan) Sdn Bhd Pledged Securities Account for Doh Jee Ming with 877,900 shares (0.22%).前四大持股人为：Liew Yoon Poh 持有 83,678,700 股（20.92%），Chan Yue Mun 持有 74,416,100 股（18.61%），Giam Teck Eng 持有 65,416,100 股（16.35%），Liew Yoon Kit 持有 65,416,100 股（16.35%）。抵押证券账户包括 Alliancegroup Nominees (Tempatan) Sdn Bhd Pledged Securities Account for Taiyang Assets Sdn Bhd 持有 2,505,700 股（0.63%），RHB Nominees (Tempatan) Sdn Bhd Pledged Securities Account For Hilary Fernandez 持有 1,332,500 股（0.33%），以及 Maybank Nominees (Tempatan) Sdn Bhd Pledged Securities Account for Doh Jee Ming 持有 877,900 股（0.22%）。
Source: annual report 2025, pages 212, 213.出处：2025 年年报第 212、213 页。
Liew Yoon Kit is the Non-Independent Non-Executive Chairman and Liew Yoon Poh is the Group Chief Executive Officer. Giam Teck Eng is one of the major shareholders. Hong Chong Chet, the Deputy Chief Executive Officer, holds a 5.0% equity interest in PT Fairmed. Hong Chong Chet was appointed on 22 November 2024 and resigned on 15 April 2025.Liew Yoon Kit 是非独立非执行主席，Liew Yoon Poh 是集团首席执行官。Giam Teck Eng 是主要股东之一。副首席执行官 Hong Chong Chet 持有 PT Fairmed 的 5.0% 股权。Hong Chong Chet 于 2024 年 11 月 22 日获委任，并于 2025 年 4 月 15 日辞职。
Source: annual report 2025, pages 12, 16, 20, 82, 83, 93.出处：2025 年年报第 12、16、20、82、83、93 页。
On 14 April 2025, the company was converted to a public limited company and assumed the name LAC Med Berhad. The company was listed on the Main Market of Bursa Malaysia Securities Berhad on 10 December 2025, with an enlarged share capital of 400 million shares, following acquisitions of LAC Medical Supplies Sdn Bhd and CVS Medical Sdn Bhd.2025 年 4 月 14 日，公司转为公众有限公司，并更名为 LAC Med Berhad。在收购 LAC Medical Supplies Sdn Bhd 与 CVS Medical Sdn Bhd 之后，公司于 2025 年 12 月 10 日在马来西亚证券交易所主板上市，扩大后股本为 400 million 股。
Source: annual report 2025, pages 27, 30, 112, 119.出处：2025 年年报第 27、30、112、119 页。
Revenue by activity, 2025 (RM million)2025 年各业务收入（百万令吉）
Source: annual report 2025, page 36.出处：2025 年年报第 36 页。
Major events大事记
Source: annual report 2025, page 7.出处：2025 年年报第 7 页。
Source: annual report 2025, page 8.出处：2025 年年报第 8 页。
Source: annual report 2025, page 119.出处：2025 年年报第 119 页。
Source: annual report 2025, page 112.出处：2025 年年报第 112 页。
Source: annual report 2025, page 45.出处：2025 年年报第 45 页。
Source: annual report 2025, page 176.出处：2025 年年报第 176 页。
Source: annual report 2025, pages 27, 101, 138.出处：2025 年年报第 27、101、138 页。
Revenue and profit营业额与盈利
Assets, borrowings and equity资产、借款与权益
20252025 年
In 2025, the company raised RM55,648,200 from the issuance of 74,197,600 ordinary shares at RM0.75 per share through its initial public offering, and paid share issuance expenses of RM4,638,004. Net cash from operating activities was RM376,349. Capital spending included RM9,462,123 for the purchase of property, plant and equipment, RM2,922,432 for additions of intangible assets; acquiring a subsidiary brought in net cash of RM304,944. Financing cash flows included proceeds of RM35,197,102 and repayments of RM32,780,289 for trade financing, proceeds of RM20,000,000 and repayments of RM15,000,000 for revolving credit, proceeds of RM10,005,775 and repayments of RM9,642,380 for invoice financing, term loan repayments of RM825,619, and dividends paid of RM5,000,000.2025 年，公司通过首次公开募股以每股 RM0.75 发行 74,197,600 股普通股，筹集 RM55,648,200，并支付了 RM4,638,004 的股份发行费用。营运活动所得现金净额为 RM376,349。资本支出包括购置物业、厂房及设备的 RM9,462,123、添置无形资产的 RM2,922,432；收购子公司则带来现金净额 RM304,944。融资现金流包括贸易融资所得 RM35,197,102 与偿还 RM32,780,289、循环信贷所得 RM20,000,000 与偿还 RM15,000,000、发票融资所得 RM10,005,775 与偿还 RM9,642,380、定期贷款偿还 RM825,619，以及支付股息 RM5,000,000。
Source: annual report 2025, pages 101, 137, 138.出处：2025 年年报第 101、137、138 页。
At year end年末情况
At 31 December 2025, cash and bank balances stood at RM30,548,627, short-term investments in money market funds at RM34,341,939, and fixed deposits with licensed banks at RM22,331,330, of which RM6,753,162 was pledged as security for banking facilities. Borrowings totaled RM27,167,874 and hire purchase payables stood at RM100,249. Net cash was RM51,494,452. Trade receivables were RM30,283,851 and contract assets were RM49,858,298, reflecting projects where work has been performed but yet to be billed. On 9 April 2026, a final dividend of 0.65 sen per ordinary share amounting to RM2,600,000 was declared, payable on 15 June 2026.截至 2025 年 12 月 31 日，现金与银行结余为 RM30,548,627，货币市场基金的短期投资为 RM34,341,939，持牌银行定期存款为 RM22,331,330，其中 RM6,753,162 已抵押作为银行授信的担保。借款总额为 RM27,167,874，租购应付款项为 RM100,249。净现金为 RM51,494,452。应收账款为 RM30,283,851，合同资产为 RM49,858,298，反映已履约但尚未开票的项目。2026 年 4 月 9 日，公司宣布派发每股普通股 0.65 仙的终期股息，总额为 RM2,600,000，将于 2026 年 6 月 15 日支付。
Source: annual report 2025, pages 37, 113, 124, 162, 187, 188, 204.出处：2025 年年报第 37、113、124、162、187、188、204 页。
Still to be spent尚未支出的资金
As at 31 December 2025, the Group had utilised RM19.0 million of the IPO proceeds, leaving RM36.6 million earmarked for identified purposes. Planned allocations include approximately RM8.0 million for the development of the EaaS and MEAMS business segments, approximately RM8.0 million to establish branch offices in Indonesia by the end of 2027, and setting up a new head office and warehouse alongside working capital.截至 2025 年 12 月 31 日，集团已动用首次公开募股所得款项中的 RM19.0 million，剩余 RM36.6 million 拨作既定用途。计划的分配包括用于发展 EaaS 与 MEAMS 业务部门的约 RM8.0 million、用于在 2027 年底前设立印度尼西亚分公司的约 RM8.0 million，以及用于设立新总部与仓库和营运资金。
Source: annual report 2025, pages 37, 45, 46.出处：2025 年年报第 37、45、46 页。
Four years of figures四年数字
Group figures, in RM, as printed in the statements.集团数字，单位令吉，照财务报表所印。
| Group集团 | 2024 | 2025 |
|---|---|---|
| RM令吉 | RM令吉 | |
| Revenue营业额 | 183,215,535 | 201,655,082 |
| Profit before taxation税前盈利 | 27,042,646 | 30,996,610 |
| Profit after taxation税后盈利 | 20,395,812 | 21,924,099 |
| Net cash from operating activities营运活动所得现金净额 | 30,670,890 | 376,349 |
| Purchase of property, plant and equipment购置物业、厂房及设备 | (501,153) | (9,462,123) |
| Dividend paid已付股息 | (18,500,000) | (5,000,000) |
| Total assets总资产 | 128,108,277 | 215,230,112 |
| Borrowings借款 | 20,213,285 | 27,167,874 |
| Cash and bank balances现金与银行结余 | 15,843,630 | 30,548,627 |
| Fixed deposits with licensed banks持牌银行定期存款 | 30,097,211 | 22,331,330 |
| Short-term investments短期投资 | 0 | 34,341,939 |
| Total equity总权益 | 47,898,454 | 118,905,174 |
On a computer, hover over a figure for the report and page it is printed on.在电脑上把鼠标移到数字上，可看到它印在哪份年报的哪一页。
Said and done说过的与做到的
Only one annual report has been read so far, so there is no later report to check its plans against.目前只读了一份年报，还没有之后的年报可以对照它的计划。
What the reports leave open年报留下待看的事
- Utilisation of the remaining RM36.6 million of IPO proceeds, including funding for the new head office and warehouse, Indonesian expansion, and EaaS and MEAMS.首次公开募股剩余 RM36.6 million 款项的动用情况，包括设立新总部与仓库、印尼扩张以及 EaaS 和 MEAMS 的资金。
Source: annual report 2025, page 37.出处：2025 年年报第 37 页。
- Execution of geographical expansion in Indonesia through PT Fairmed, which plans to establish branch offices in Sumatra, Surabaya, and Kalimantan by the end of 2027.通过 PT Fairmed 执行在印度尼西亚的地域扩张，该公司计划在 2027 年底前在苏门答腊、泗水和加里曼丹设立分公司。
Source: annual report 2025, pages 29, 46.出处：2025 年年报第 29、46 页。
- Realisation and collection of contract assets of RM49,858,298 and trade receivables of RM30,283,851 outstanding at year end.年末结存的 RM49,858,298 合同资产和 RM30,283,851 应收账款的变现与回收情况。
Source: annual report 2025, pages 37, 124.出处：2025 年年报第 37、124 页。
- Implementation of the enterprise PACS project across 30 hospitals under the partnership with KPJ Healthcare Berhad.与 KPJ Healthcare Berhad 合作在 30 家医院实施企业级 PACS 项目的推进情况。
Source: annual report 2025, pages 8, 45.出处：2025 年年报第 8、45 页。
Facts as printed in the company's annual reports, with the page of each; no rating and no advice. Built 2026-11-02.内容为公司年报所印的事实，并注明页码；不评级，不构成投资建议。生成日期 2026-11-02。